Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.72 |
| ▸ | NPC1 | O15118 | 8/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | MMP1 | P03956 | 1/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31111478 | 1.00 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL6850971 | 0.84 | RAB9A (0.75) | RAB9ANPC1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL30851501 | 0.84 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL11202950 | 0.84 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL3904710 | 0.84 | RAB9A (0.52) | RAB9ANPC1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL29519193 | 0.83 | SMN1; SMN2 (0.54) | RAB9ANPC1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL1226530 | 0.83 | SMN1; SMN2 (0.54) | RAB9ANPC1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL440095 | 0.83 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL2089517 | 0.83 | KMT2A (0.52) | RAB9ANPC1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL157188 | 0.82 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893200-B1 | CARBAMATE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2010-09-29 | — | — | EP | claimed |
| US-20090082399-A1 | Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2009-03-26 | — | — | US | claimed |
| EP-1893200-A2 | CARBAMATE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2008-03-05 | — | — | EP | claimed |
| EP-1799673-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006123244-A2 | CARBAMATE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | claimed |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-13 | — | — | US | claimed |
| WO-2006044528-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | claimed |
| US-20240043427-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2022250069-A1 | SULFUR-CONTAINING PYRAZOLE COMPOUND AND NOXIOUS ORGANISM CONTROL AGENT INCLUDING SULFUR-CONTAINING PYRAZOLE COMPOUND AS ACTIVE INGREDIENT | 三井化学アグロ株式会社 | 2022-12-01 | — | — | WO | disclosed |
| US-20220062281-A1 | INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION | NAT CENTRE FOR BIOLOGICAL SCIENCES TIFR (IN) | 2022-03-03 | — | — | US | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| CN-1390219-A | Pyrazolopyrimidines as therapeutic agents | ABBOTT AG (DE) | 2003-01-08 | — | — | CN | disclosed |
| CN-1335849-A | Pyrrolopyrimidines as protein kinase inhibitors | BASF AG (DE) | 2002-02-13 | — | — | CN | disclosed |
| EP-1042277-A1 | NAPHTHALENE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032435-A1 | NAPHTHALENE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| JP-S646250-A | CARBAMATE DERIVATIVE, ITS PRODUCTION AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE CONTAINING SAID DERIVATIVE AS ACTIVE COMPONENT | SUMITOMO CHEMICAL CO | 1989-01-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | RAB9A 2873/4885NPC1 2281/4885SMN1; SMN2 3774/4885 |
| US-20090082399-A1 | Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors | GRM5, GRIK5, GRM1 | RAB9A 723/4885NPC1 2603/4885SMN1; SMN2 3376/4885 |
| US-20240043427-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | RAB9A 2873/4885NPC1 2281/4885SMN1; SMN2 3774/4885 |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | RAB9A 1437/4885NPC1 4728/4885SMN1; SMN2 1922/4885 |
| US-20220062281-A1 | INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION | CD4, CD14, CD69 | RAB9A 997/4885NPC1 77/4885SMN1; SMN2 4574/4885 |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | RAB9A 2461/4885NPC1 1210/4885SMN1; SMN2 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.